Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2023Business Wire • 05/11/23
Summit Therapeutics Announces First Patient Treated in Phase III HARMONi Clinical Trial Evaluating Ivonescimab (SMT112)Business Wire • 05/09/23
Summit Therapeutics Announces Initial Indications for Clinical Trials for Ivonescimab (SMT112)Business Wire • 05/03/23
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Summit Therapeutics Inc. and Encourages Investors with Losses to Contact the FirmBusiness Wire • 03/20/23
Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2022Business Wire • 03/09/23
Summit Therapeutics Announces Timing for Rights Offering for Up to $500 MillionBusiness Wire • 01/30/23
Summit Therapeutics Closes Deal with Akeso Inc. to In-License Breakthrough Innovative Bispecific AntibodyBusiness Wire • 01/20/23
Summit Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare ConferenceBusiness Wire • 01/05/23
Akeso Inc. Announces Collaboration and License Agreement for Up to US$5 Billion with Summit Therapeutics to Accelerate Global Development and Commercialization of its Breakthrough Bispecific Antibody, Ivonescimab (PD-1/VEGF)PRNewsWire • 12/06/22
Summit Therapeutics Partners with Akeso Inc. in Deal for Up to $5 Billion to In-License Breakthrough Innovative Bispecific AntibodyGlobeNewsWire • 12/06/22